Ophthalmology Innovation Summit - Retina

Name: EyePoint Pharmaceuticals
Uploaded: 2018-07-23T15:21:00+00:00
Description: Tom Hadley, Vice President, Marketing and Sales, EyePoint Pharmaceuticals, talks about the focus of the new eye care company and gives an update on its new drug application for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis.

OIS Retina: 2018

EyePoint Pharmaceuticals

Tom Hadley

Show Description +

Tom Hadley, Vice President, Marketing and Sales, EyePoint Pharmaceuticals, talks about the focus of the new eye care company and gives an update on its new drug application for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis.

Posted: 7/23/2018

Up Next

Zeiss

ZeaVision Holdings

Pinakin Davey, OD, PhD

iRenix

Stephen Smith, MD

Clearside Biomedical

Brion Raymond

Aerie Pharmaceuticals

Vince Anido Jr, PhD

Spark Therapeutics

Paulo Falabella, MD, PhD

Allegro

Vicken Karageozian, MD

Eyedaptic

Jay Cormier

GenSight Biologics

Barrett Katz, MD

RFE Pharma

Alan Franklin, MD, PhD

Back to All Videos

EyePoint Pharmaceuticals

Tom Hadley

Tom Hadley, Vice President, Marketing and Sales, EyePoint Pharmaceuticals, talks about the focus of the new eye care company and gives an update on its new drug application for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis.

Posted: 7/23/2018